Loading...
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
OBJECTIVE: Primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. Sensitivity to anti-EGFRs (Epidermal Growth Factor Receptor) of metastatic transverse colon cancers (mTCCs) has usually been assumed similar to right-sided tumours; however, evidence about the clinic...
Na minha lista:
| Udgivet i: | ESMO Open |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6435314/ https://ncbi.nlm.nih.gov/pubmed/30962964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000489 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|